HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib

Figure 5

Wound healing assay in HCC827 GR cells with different treatments. HCC827 GR cells were pretreated with different treatments (blank control, YC-1, gefitinib, YC-1, and gefitinib combined, for 16 h and 28 h) before receiving the wound healing assay. (a) Wound healing status of HCC827 GR cells with different treatments for 16 h was presented after wounding for 12 and 24 h (magnification, ×100). (b) Wound-healing percentages after wounding for 12 and 24 h were calculated to evaluate cell migration ability of HCC827 GR cells with different treatments for 16 h. (c) Wound healing status of HCC827 GR cells with different treatments for 28 h was presented after wounding for 12 and 24 h (magnification, ×100). (d) Wound-healing percentages after wounding for 12 and 24 h were calculated to evaluate cell migration ability of HCC827 GR cells with different treatments for 28 h. The concentration of YC-1 was 40 μM, and the final concentration of gefitinib was 20 nM. Error bars represented the . Data were obtained from three independent experiments. and .

(a)

(b)

(c)

(d)